Combination therapy with BRAFi and MEKi has remarkably improved survival in the adjuvant setting for patients with BRAF mutant melanomas, and combining a BRAFi and an EGFRi has improved tumor regression in BRAF mutant colorectal cancer xenografts [51, 54]. Here, BRAF is linked to colorectal cancer.